Scottsdale Research Institute is a Phoenix-based clinical trials site that is dedicated to advancing the state of medical care through rigorous research. SRI strives to conduct high quality, controlled scientific studies intended to ascertain the general medical safety and efficacy of cannabis and cannabis products and examine various forms of cannabis administration. SRI is currently conducting the only federally-authorized study of medical cannabis for Post-Traumatic Stress Disorder (PTSD) for military veterans in the United States.
Scottsdale Research Institute (SRI) is currently conducting an FDA- and DEA-authorized Phase 2 clinical research study of medical cannabis (marijuana) for Post-traumatic Stress Disorder (PTSD) in military veterans.
The purpose of the Scottsdale Research Institute, LLC, an Arizona-based Limited Liability Company is to coordinate rigorous, scientific studies to assess the safety and efficacy of cannabis and cannabis compounds for treating medical conditions.
Focused coordination of rigorous, scientific studies to assess the safety and efficacy of cannabis and cannabis compounds for treating medical conditions is what the team at SRI does on a daily basis.
SRI is a team of highly educated professionals providing excellence in both research and day to day operations.
The California-based Multidisciplinary Association for Psychedelic Studies (MAPS), founded in 1986, is conducting the study with the help of a $2.16 million grant from the Colorado Department of Public Health and Environment.
SRI is the first participant in this clinical trial designed to evaluate the effectiveness of smoking marijuana to treat PTSD in veterans.